Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 6/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 6/20 | 0.33 |
| ▸ | GRIK2 | Q13002 | 5/20 | 0.33 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.31 |
| ▸ | BLM | P54132 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.31 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.31 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.31 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.31 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18607704 | 0.74 | GRIK1 (0.39) | GRIK1GRIK2GRIA2GRIA4GRIK3 | |
| SCHEMBL14567322 | 0.71 | TP53 (0.35) | GRIK1GABRR1GRIK2 | |
| SCHEMBL2593184 | 0.71 | — | — | |
| SCHEMBL28075191 | 0.70 | GABRR1 (0.45) | GRIK1GABRR1GRIK2 | |
| SCHEMBL18607602 | 0.69 | — | — | |
| SCHEMBL20861920 | 0.68 | GABRR1 (0.38) | GRIK1GABRR1GRIK2GRIA2GRIA4 | |
| SCHEMBL5433572 | 0.67 | — | — | |
| SCHEMBL28130520 | 0.67 | CPB2 (0.41) | GABRR1GABRR2BLMLMNAGABRR3 | |
| Crotonic Acid SCHEMBL11681776 | 0.65 | — | — | |
| Crotonic Acid SCHEMBL8626250 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200345735-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2020-11-05 | — | — | US | disclosed |
| US-20180169099-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-9717730-B2 | Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use | GENENTECH, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9610289-B2 | Combinations of AKT inhibitor compounds and erlotinib, and methods of use | GENENTECH, INC. (US) | 2017-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180169099-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | GRIK1 4113/4885GABRR1 3698/4885GRIK2 4331/4885 |
| US-20200345735-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | GRIK1 4113/4885GABRR1 3698/4885GRIK2 4331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.